ABP Pediatric Hematology-Oncology Practice Questions - ABP Pediatric Hematology-Oncology Subspecialty Certification Examination Exam

Tisagenlecleucel is approved for pediatric relapsed/refractory B-ALL. What is its mechanism?

Anti-CD22 antibody-drug conjugate Bispecific CD19xCD3 T-cell engager Autologous T cells engineered to express a CD19-directed chimeric antigen receptor Anti-CD20 monoclonal antibody

Correct Answer:

Autologous T cells engineered to express a CD19-directed chimeric antigen receptor

Access more questions from this quiz

Continue to ABP Pediatric Hematology-Oncology Practice Questions - ABP Pediatric Hematology-Oncology Subspecialty Certification Examination Exam for more practice questions and the full quiz experience.

Access More Questions